Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Nasopharyngeal Carcinoma 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Virus Diseases 1Urethral Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Liver Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

rofecoxib 1lenvatinib 1Gemcitabine 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced Non-small Cell Lung Cancer × Gemcitabine × Clear all
NCT00385606 2023-03-23

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

National Cancer Institute, Naples

Phase 2/3 Completed
400 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡